DermatopathologyDermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
Section snippets
Checkpoint inhibitors
Checkpoints maintain immunologic homeostasis by limiting T-lymphocyte activity toward host antigens but can also inadvertently decrease immune surveillance of cancer cells.3, 4, 5 CTLA-4, expressed on the cell surface of activated T cells, prevents continued T-cell activation when bound to costimulatory signals. Ipilimumab blocks this interaction, allowing the immune system to activate against neoplastic cells.6, 7, 8, 9 Similarly, binding of PD-1 expressed on activated T cells prevents T-cell
Predominantly superficial perivascular dermatitis
Maculopapular eruptions, occurring in up to 60% of patients treated with CTLA-4 inhibitor therapy, typically show superficial perivascular dermatitis on histopathology. Perivascular dermatitis, occasionally with eosinophils, may occur during PD-1 blockade but is less common.47 Patients demonstrate variably pruritic, erythematous macules and dome-shaped papules, some of which coalesce into patches and plaques.42,44,45,48 Reticulated patterns or koebnerization can be seen.43,44 Eruptions usually
Conclusions
Immune checkpoint blockade has demonstrated remarkable outcomes for patients with various types of cancer. Checkpoint inhibitors are associated with a range of cutaneous AEs, highlighting the complexity of the immune response and the importance of clinical-histopathologic correlation in accurate recognition of AEs, allowing for appropriate intervention and patient care.
References (135)
- et al.
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Curr Opin Immunol
(2012) - et al.
Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies
Semin Oncol
(2015) - et al.
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Eur J Cancer
(2019) - et al.
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Ann Oncol
(2015) - et al.
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
Ann Oncol
(2010) - et al.
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
Eur J Cancer
(2016) - et al.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Lancet
(2017) - et al.
The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis
J Am Acad Dermatol
(2013) - et al.
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort
J Am Acad Dermatol
(2016) - et al.
Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
J Am Acad Dermatol
(2018)
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Eur J Cancer
Clinical perspectives and murine models of lichenoid tissue reaction/interface dermatitis
J Dermatol Sci
Pityriasis lichenoides chronica-like drug eruption developing during pembrolizumab treatment for metastatic melanoma
JAAD Case Rep
Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients
Eur J Cancer
Ipilimumab in patients with cancer and the management of dermatologic adverse events
J Am Acad Dermatol
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
Ann Oncol
Grover's disease: clinicopathologic review of 72 cases
Mayo Clinic Proc
Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab
J Am Acad Dermatol
Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma
JAAD Case Rep
Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma
Chest
Ipilimumab-associated Sweet syndrome in a melanoma patient
J Am Acad Dermatol
Immune checkpoint blockade in cancer therapy
J Clin Oncol
The blockade of immune checkpoints in cancer immunotherapy
Nat Rev Cancer
Inhibitory B7-family molecules in the tumour microenvironment
Nat Rev Immunol
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Nat Med
CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers
Cancer Immunol Immunother
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy
Annu Rev Immunol
Immunostimulatory monoclonal antibodies for cancer therapy
Nat Rev Cancer
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
Ann N Y Acad Sci
Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb
Curr Opin Mol Ther
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
Embo J
Restoring function in exhausted CD8 T cells during chronic viral infection
Nature
PD-1 and its ligands in tolerance and immunity
Annu Rev Immunol
At the bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy
J Leukoc Biol
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
Nat Med
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
J Exp Med
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Proc Natl Acad Sci U S A
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
N Engl J Med
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma
Clin Cancer Res
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
J Immunother Cancer
Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy
Clin Cancer Res
Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes
Clin Cancer Res
Pembrolizumab cutaneous adverse events and their association with disease progression
JAMA Dermatol
Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis
J Clin Oncol
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
J Cutan Pathol
Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy
Am J Clin Dermatol
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
Transl Lung Cancer Res
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma
Clin Cancer Res
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
J Immunother Cancer
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
N Engl J Med
Cited by (86)
Two novel cases of delayed drug rash after immune checkpoint inhibitors and platin combination treatment
2024, Annals of Allergy, Asthma and ImmunologyPustular psoriasis triggered by therapy with atezolizumab and bevacizumab
2024, Anais Brasileiros de DermatologiaPembrolizumab-induced lichenoid dermatitis treated with dupilumab
2023, JAAD Case ReportsDrug-Induced Subcutaneous Sweet Syndrome
2023, Mayo Clinic Proceedings
Funding sources: The research reported in this publication was supported in part by the Dermatology Foundation, through Dermatopathology Career Development Award (Dr Kiuru); National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number K23AR074530 (Dr Kiuru); Berg, Lutris, Paxman, Novocure, US Biotest, and Veloce (Dr Lacouture); and the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30-CA0-08748 and National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number U01AR077511 (Dr Lacouture).
Conflicts of interest: Dr Lacouture has a consultant/speaking role with Legacy Healthcare Services, Adgero, Amryt, Celldex, Debiopharm, Galderma, Johnson and Johnson, Novocure, Lindi, Merck Sharp and Dohme, BMS, Helsinn, Janssen, Menlo, Novartis, F. Hoffmann-La Roche AG, AbbVie Inc, Boehringer Ingelheim, Allergan, Amgen, E.R. Squibb & Sons LLC, EMD Serono, AstraZeneca, Genentech, LEO Pharma, Seattle Genetics, Bayer, Lutris, Pierre Fabre, Paxman Coolers, Adjucare, Dignitana, Biotechspert, Teva, Parexel, OnQuality, Novartis, Harborside, Wiley, Azitra, NCODA, and Takeda Millenium. Drs Ellis, Vierra, Millsop, and Kiuru have no conflicts of interest to declare.
IRB approval status: Not applicable.
Reprints not available from the authors.